Exendin-4 Microparticle Formulation for Lean Mass Preservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating obesity and type II diabetes often result in loss of lean body mass, and there is a need for effective weight reduction methods that spare lean body mass and maintain metabolic health.
Innovation Solution
A formulation comprising exendin-4, a biocompatible polymer, and a sugar, administered subcutaneously once weekly to maintain sustained plasma concentrations, which includes a long-acting formulation with poly(lactide-co-glycolide) microparticles and sucrose, releasing exendin-4 over a period of time to treat type II diabetes and reduce body weight.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If standard diets and exercise are used for weight loss, then body weight is reduced, but lean body mass is lost
Solution Approach 1:
The patent changes the physiological parameters by administering exendin-4 at controlled plasma concentrations (170-350 pg/ml) to alter the body's metabolic response to caloric restriction. This hormonal intervention modifies how the body handles protein catabolism during weight loss, allowing fat loss while preserving lean mass through pharmacological parameter adjustment rather than dietary changes alone
Solution Approach 2:
Exendin-4 acts as an intermediary substance that mediates between caloric restriction and lean body mass preservation. The peptide hormone intermediate modifies the physiological pathway between energy deficit and muscle protein breakdown, enabling weight loss without the typical associated muscle wasting through its action on glucose-dependent insulinotropic polypeptide receptors
2Quantity of substance
If caloric restriction is applied for weight loss, then body weight is reduced, but nitrogen balance becomes negative and lean body mass is lost
Solution Approach 1:
The patent changes the nitrogen balance parameter by maintaining plasma exendin-4 concentrations that specifically protect against protein catabolism during caloric restriction. The hormonal intervention alters the metabolic parameter of nitrogen excretion, allowing caloric deficit for weight loss while maintaining positive or neutral nitrogen balance through reduced urinary nitrogen loss and preserved protein synthesis
3Ease of operation
If once-weekly administration is used, then patient compliance is improved, but maintaining sustained plasma concentrations becomes more difficult
Solution Approach 1:
The patent achieves continuous therapeutic effect through once-weekly administration by utilizing the prolonged half-life and sustained action of exendin-4 when formulated with specific excipients and delivery mechanisms. The formulation maintains continuous plasma concentrations within the therapeutic window (170-350 pg/ml) throughout the week, ensuring uninterrupted metabolic intervention while eliminating daily injection requirements for patient compliance
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.